How to evaluate Medicaid buy-in proposals

In the midst of threats to the Affordable Care Act and pushes for more dramatic shifts to single-payer healthcare, some Democrats in Congress and state legislatures have begun proposing a different option: allowing people to buy into Medicaid. But not all those proposals would achieve their goals in the same way, argue Duke University researcher David Anderson, MSPPM, and Harvard University PhD student and former CMS spokesperson Emma Sandoe.

Writing in a blog for Health Affairs, Anderson and Sandoe said Medicaid buy-in proposals can be largely divided into two camps: those which would require a CMS waiver to create a new eligibility category in Medicaid and policies which would use the framework of managed care contracts to offer a “public option” on ACA exchanges.

Both methods share common goals, like offering a lower-cost option than the current plans on the exchanges, where premiums on popular silver-level plans jumped by an average of 34 percent for 2018 coverage. Pricing those plans would be a challenge, Anderson and Sandoe wrote, and create an unintended consequence for other ACA customers.

“The introduction of more low-price plans may reduce the benchmark plan price, which determines the amount of premium subsidies for those who are eligible,” they wrote. “A lower-cost benchmark would raise effective premiums for many subsidized buyers. This problem disappears if Medicaid buy-in is only offered on a nonsubsidized basis.”

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel. 

Kit Crancer, RBMA board member, speaks with Radiology Business about key legislative developments on the Hill that will affect the specialty.